Czer L S C, Ruzza A, Vespignani R, Jordan S, De Robertis M A, Mirocha J, Gallagher S P, Patel K, Schwarz E R, Kass R M, Trento A
Division of Cardiology, Cedars-Sinai Heart Institute, Los Angeles, California 90048, USA.
Transplant Proc. 2011 Dec;43(10):3869-76. doi: 10.1016/j.transproceed.2011.08.095.
The role of solid multiorgan transplantation remains to be determined. We compared our experience with combined heart-kidney transplantation (HKT) and heart transplant alone (HT), and assessed patient survival rates and freedom from allograft rejection in these two patient groups.
We reviewed the clinical outcomes of patients undergoing HKT (n=30) or HT (n=440) between June 1992 and March 2009. Baseline patient characteristics, perioperative factors, incidence of rejection, and survival were examined.
There were no significant differences between the two groups for age, gender, etiology of heart disease, functional class, preoperative left ventricular ejection fraction, end-diastolic diameter, cardiac output, or transplant waitlist status. Patients with HKT had a higher serum creatinine level (P<.001) and a greater incidence of hypertension (P=.04). No differences were found in cardiac allograft ischemic times, including cardiopulmonary bypass or cross-clamp times. Kidney allograft ischemic time was 14.6±9 hours (mean±SD; range, 4 hours to 49 hours). Kaplan-Meier survival estimates were similar for the HKT and HT groups at 30 days (93%±4.6% versus 98%±0.7%), 1 year (87%±6.2% versus 93%±1.2%), 5 years (68%±9.0% versus 76%±2.1%), and 10 years (51%±11% versus 53%±3.0%; P=.54 for all comparisons). Follow-up serum creatinine levels were similar after HKT and HT at 30 days (1.6±1.8 mg/dL versus 1.1±0.4 mg/dL), 1 year (1.4±0.6 mg/dL versus 1.5±0.6 mg/dL), and 5 years (1.8±1.8 mg/dL versus 1.8±1.2 mg/dL; P>.05 for all comparisons).
HKT offers excellent survival and similar renal function when compared with HT alone. Patients with end-stage cardiac and renal failure can be considered for HKT.
实体多器官移植的作用仍有待确定。我们比较了心脏-肾脏联合移植(HKT)和单纯心脏移植(HT)的经验,并评估了这两组患者的生存率和移植后无排斥反应情况。
我们回顾了1992年6月至2009年3月期间接受HKT(n = 30)或HT(n = 440)的患者的临床结局。检查了患者的基线特征、围手术期因素、排斥反应发生率和生存率。
两组在年龄、性别、心脏病病因、功能分级、术前左心室射血分数、舒张末期直径、心输出量或移植等待名单状态方面无显著差异。HKT患者的血清肌酐水平较高(P <.001),高血压发生率较高(P =.04)。在心脏移植的缺血时间方面,包括体外循环或主动脉阻断时间,未发现差异。肾脏移植的缺血时间为14.6±9小时(平均值±标准差;范围为4小时至49小时)。HKT组和HT组在30天时的Kaplan-Meier生存估计相似(93%±4.6%对98%±0.7%),1年时(87%±6.2%对93%±1.2%),5年时(68%±9.0%对76%±2.1%),10年时(51%±11%对53%±3.0%;所有比较的P =.54)。HKT组和HT组在30天时的随访血清肌酐水平相似(1.6±1.8mg/dL对1.1±0.4mg/dL),1年时(1.4±0.6mg/dL对1.5±0.6mg/dL),5年时(1.8±1.8mg/dL对1.8±1.2mg/dL;所有比较的P>.05)。
与单纯HT相比,HKT具有良好的生存率和相似的肾功能。终末期心脏和肾衰竭患者可考虑进行HKT。